Compare AbbVie Inc (ABBV) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Financial Select Sector SPDR Fund — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Financial Select Sector SPDR Fund trades at $54.97. The key difference: AbbVie Inc pays a 2.72% dividend while Financial Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| ABBV | XLF | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $56.41 |
52-Week Low | $184.85 | $47.80 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
XLF trades at $56.15, up 0.95% with strong technical momentum as moving averages signal bullish alignment. The ETF faces pivotal Q2 earnings season with major bank components reporting, while regulatory developments and potential rate hikes create both opportunities and headwinds. Recent Federal Reserve stress test results have enabled increased dividends, with XLF announcing a $0.19 dividend for H1-2026.
The financial sector ETF shows technical strength but faces fundamental tests from earnings season and regulatory uncertainty. Upside potential exists from dividend growth and potential rate hike benefits, while risks include AI cybersecurity threats and election-driven market volatility that could pressure financial stocks in H2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
